Co-Diagnostics Q2 FY26 net loss narrows to USD 6.3 million; revenue rises to USD 166,131

• Co-Diagnostics posted a GAAP net loss of $6.3 million, or $1.46 per share, in Q2 2026.
• Operating loss narrowed to $6.2 million as operating expenses fell to $6.3 million on lower G&A and R&D spending.
• Revenue edged up to $166,131, supported by higher product revenue; cash and cash equivalents ended at $3.6 million.
• Non-GAAP adjusted EBITDA loss improved to $5.8 million from a $7.2 million loss a year earlier.
• Submitted an FDA 510(k) plus a concurrent CLIA waiver application for its Flu A/B & RSV test; expanded Vector Smart installations to 21 states.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608131601PR_NEWS_USPR_____LA26231) on August 13, 2026, and is solely responsible for the information contained therein.